Abstract
Background/purpose
Thrombocytopenia due to hypersplenism precludes percutaneous liver biopsy in many cases of chronic liver disease (CLD). The aim of this study was to assess the efficacy of propranolol in correcting platelet counts (>100,000/mm3) to ensure percutaneous liver biopsy in children with CLD.
Methods
From January 2005 to December 2012, 51 consecutive children (mean age 11.5 ± 3.0 years, 34 boys) with CLD who needed liver biopsy but could not be done due to hypersplenism-related thrombocytopenia (platelets <100,000/mm3 and/or total leukocyte counts <4,000/mm3 with splenomegaly) were recruited and given a 4-week trial of long-acting propranolol (1.5–2 mg/kg/day). Hemodynamic parameters and splenic artery hemodynamics by Doppler ultrasound were recorded before and after the propranolol trial. Response to therapy was defined as improvement of platelet counts to ≥105/mm3.
Results
Thirty-two (62.7 %) children responded to propranolol therapy and their mean platelet counts increased from 57.5 ± 13.0 × 103 to 140.7 ± 43.3 × 103/mm3, p = 0.0001. Liver biopsy could be done in 29. While comparing responders with non-responders, baseline spleen size (7.4 ± 3.3 vs. 12.7 ± 4.5 cm, p = 0.0001) and platelet counts (57.5 ± 13.0 × 103 vs. 39.5 ± 14.5 × 103, p = 0.0001) were found to be significant. ROC curve suggested a cut-off value of ≤8.5 cm of spleen and ≥53,000 platelets as predictors of response. With propranolol, mean arterial pressure and spleen size reduced (p < 0.05) and splenic artery resistance increased significantly (p = 0.005) in responders.
Conclusions
Propranolol corrects thrombocytopenia and makes liver biopsy possible in almost two-thirds of cases by reducing splenic sequestration through splenic artery vasoconstriction. The baseline spleen size and platelet counts determine the effectiveness of therapy. A trial of β-blocker is worth carrying out in cases where liver biopsy is contraindicated due to hypersplenism-related thrombocytopenia.
Similar content being viewed by others
References
Poddar U, Thapa BR, Rao KL, Singh K. Etiological spectrum of esophageal varices due to protal hypertension in Indian children: is it different from the West? J Gastroenterol Hepatol 2008;23:1354–1257
Arora NK, Arora S, Ahuja A, Mathur P, Maheshwari M, Das MK, et al. Alpha 1 antitrysin deficiency in children with chronic liver disease in north India. Indian Pediatr 2010;47:1015–1023
Mileti E, Rosenthal P, Peters MG. Validation and modification of simplified diagnotic criteria for autoimmune hepatitis in children. Clin Gastroenterol Hepatol 2012;10:417–421.e1–e2 doi: 10.1016/j.cgh.2011.11.030. Epub 2011 Dec 15
Sarin SK, Kumar A, Chawla YK, Baijal SS, Dhiman RK, Jafri W, Members of the APASL Working Party on Portal Hypertension, et al. Noncirrhotic portal fibrosis/idiopathic portal hyepertension: APASL recommendations for diagnosis and treatment. Hepatol Int 2007;1:398–413 doi:10.1007/s12072-007-9010-9 Epub 2007 Sep 11
Liangpunsakul S, Ulmer BJ, Chalasani N. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci 2003;326:111–116
Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000;95:2936–2939
El-Khishen MA, Henderson JM, Millikan WJ, Kutner MH, Warren WD. Splenectomy is contraindicated for thrombocytopenia secondary to portal hypertension. Surg Gynecol Obstet 1985;160:233–238
McCormick PA, Walker S, Benepal R. Hypersplenism is related to age of onset of liver disease. Ir J Med Sci 2007;176:293–296
Krishna YR, Yachha SK, Srivastava A, Negi D, Lal R, Poddar U. Quality of life in children managed for extrahepatic portal venous obstruction. J Pediatr Gastroenterol Nutr 2010;50:531–536 doi:10.1097/MPG.0b013e3181b6a55d
Aoki Y, Hiari K, Tanikawa K. Mechanism of thrombocytopenia in liver cirrhosis. Kinetics of Indium-111 tropolone labeled platelets. Eur J Nuclear Med 1993;20:123–129
Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of “Hypersplenic” thrombocytopenia. J Clin Invest 1966;45:645–657
Sakai K, Iwao T, Oho K, Toyonaga A, Sata M. Propranolol ameliorates thrombocytopenia in patients with cirrhosis. J Gastroenterol 2002;37:112–118
Paquet KJ. Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices—a prospective controlled randomized trial. Endoscopy 1982;14:4–5
Taylor KJ, Holland S. Doppler ultrasound. I. Basic principles, instrumentation and pitfalls. Radiology 1990;174:297–307
Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver Diseases. Liver biopsy Hepatology 2009;49:1017–1044 doi:10.1002/hep.22742
Scheimann AO, Barrios JM, Al-Tawil YS, Gray KM, Gilger MA. Percutaneous liver biopsy in children: impact of ultrsonography and spring-loaded biopsy needles. J Pediatr Gastroenterol Nutr 2000;31:536–539
Hillon P, Lebrec D, Munoz C, Jungers M, Goldfarb G, Benhamou JP. Comparison of effects of a cardioselective and a nonselective β-blocker on portal hypertension in patient with cirrhosis. Hepatology 1982;2:528–531
Westaby D, Bihari DJ, Gimson AE, Crossley IR, Williams R. Selective and non-selective β receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension. Gut 1984;25:121–124
Kroeger R, Groszmann RJ. The effect of selective blockade of β-2 adrenergic receptors on portal and systemic hemodynamics in portal hypertensive rat model. Gastroenterology 1985;88:896–900
Bolognesi M, Sacerdoti D, Merkel C, Gerunda G, Maffei-Faccioli A, Angeli P, et al. Splenic Doppler impedence indices: influence of different portal hemodynamic conditions. Hepatology 1996;23:1035–1040
Sacerdoti D, Gaiani S, Buonamico P, Merkel C, Zoli M, Bolondi L, et al. Interobserver and interequipment variability of hepatic, splenic and renal arterial Doppler resistance indices in normal subjects and patients with cirrhosis. J Hepatol 1997;27:986–992
de Oliveira CA, de Sa RA, Velarde LG, Monteiro VN, Netto HC. Doppler velocity of the ophthalmic artery. J Ultrasound Med 2012;31:879–884
Hollis B, Mavrides E, Campbell S, Tekay A, Thilaganathan B. Reproducibility and repeatability of transabdominal uterine artery Doppler velocimetry between 10 and 14 weeks of gestation. Ultrasound Obstet Gynecol 2001;18:593–597
Bolognesi M, Sacerdoti D, Merkel C, Gatta A. Duplex Doppler sonographic evaluation of splanchnic and renal effects of single agent and combined therapy with nadolol and isosorbide-5-mononitrate in cirrhotic patients. J Ultrasound Med 1994;13:945–952
Iwao T, Oho K, Sakai T, Sato M, Nakano R, Yamawaki M, et al. Noninvasive hemodynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol. J Hepatol 1998;28:847–855
Berzigotti A, Rinaldi MF, Magalotti D, Morelli MC, Zappoli P, Andreone P, et al. Primary prophylaxis with nadolol in cirrhotic patients: doppler patterns of splanchnic hemodynamics in good and poor responders. J Hepatol 2006;44:310–316
Sabba C, Buonamico P, Vendemiale G, Berardi E, Antonica G, Palmieri V, et al. Hemodynamic effects of propranolol, octreotide and their combination during fasting and post-prandial splanchnic hyperemia in patients with cirrhosis. Eur J Gastroenterol Hepatol 2001;13:163–169
Landolifi R, Leone G, Fedeli G, Storiti S, Laghi F, Bizzi B. Platelet associated IgG in acute and chronic hepatic disease. Scand J Hematol 1980;25:417–422
Asenia P, Frangi M, Beati C, Vertemati M, Romani F. Is thrombocytopenia in liver failure dependent on an inadequate synthesis of thrombopoietic stimulating factor by the liver? Med Hypothesis 1988;26:217–219
Alvarez OA, Lopera GA, Patel V, Encarnacion CE, Palmaz JC, Lee M. Improvement of thrombocytopenia due to hypersplenism after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients. Am J Gastroenterol 1996;91:134–137
Gschwantler M, Vavrik J, Gebauer A, Kriwanek S, Schrutka-Kolbl C, Fleischer J, et al. Course of platelet counts in cirrhotic patients after implantation of transjugular intrahepatic portosystemic shunt- a prospective, controlled study. J Hepatol 1999;30:254–259
Puttini M, Marni A, Montes F, Belli L. Effect of portosystemic shunt on hypersplenism: clinical study in 129 patients with cirrhosis. Am Surg 1979;45:444–448
Marni A, Trojsi C, Belli L. Distal splenorenal shunt: hemodynamic advantage over total shunt and influence on clinical status, hepatic function and hypersplenism. Am J Surg 1981;142:372–376
Sangro B, Bilbao I, Herrero I, Corella C, Longo J, Beloqui O, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology 1993;18:309–314
Nio M, Hayashi Y, Sano N, Ishii T, Sasaki H, Ohi R. Long-term efficacy of partial splenic embolization in children. J Pediatr Surg 2003;38:1760–1762
Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:1–31 doi:10.1002/hep.23584
Poddar U, Thapa BR, Puri P, Girish CS, Vaiphei K, Vashishta RK, et al. Non-cirrhotic portal fibrosis in children. Indian J Gastroenterol 2000;19:12–13
Poddar U, Thapa BR, Vashishta RK, Girish CS, Singh K. Congenital hepatic fibrosis in Indian children. J Gastroenterol Hepatol 1999;14:1192–1196
Acknowledgements
We acknowledge the contribution of Dr. Jagadeesh R, Dr. Anuj Thakral, Dr. Madhvi Verma for helping us in facilitating the Doppler study. This paper was presented at the 21st United European Gastroenterology Week (UEGW 2013), Berlin, Germany, October 12–16, 2013.
Compliance with ethical requirements and Conflict of interest
Informed consent was obtained from parents of all participating children. All procedures performed in this study were in accordance with the ethical standards of the institute and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. Ujjal Poddar, Upender Shava, Surender K Yachha, Jaya Agarwal, Sheo Kumar, Sanjay S Baijal, and Anshu Srivastava declare that they have no conflict of interest and ethical standards were maintained in this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Poddar, U., Shava, U., Yachha, S.K. et al. β-Blocker therapy ameliorates hypersplenism due to portal hypertension in children. Hepatol Int 9, 447–453 (2015). https://doi.org/10.1007/s12072-014-9575-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-014-9575-z